Skip to content

Serum or Plasma Anti-SARS-CoV-2 Nucleocapsid Antibody, Immunoassay

Published: August 9, 2026Updated: August 16, 2026

This test measures antibodies in your blood that your immune system produces in response to the SARS-CoV-2 virus, which causes COVID-19. It helps determine if you’ve been exposed to the virus and whether your body has developed immunity.

Quick summary

["This test checks for past infection by detecting antibodies to a key viral protein."]

Medically reviewed by WellAlly Editorial TeamLast reviewed August 16, 2026Editorial policy

Key facts at a glance

LOINC
5356-1
Short code
ENA SM Ab Ser Ql IA
Synonyms
ENA SM Ab Ser Ql IA
Category
chemistry
Sample
serum
Container
Red-top tube (SST)
Units
N/A
Fasting
false
Population
adult
Sex
all
Age range
18–65 years
Method
ia
Specimen volume
5 mL
Stability
Room temperature: 4h, Refrigerated: 24h, Frozen: 7d
Hemolysis max
500
Lipemia max
1000
Icterus max
500
TAT
4–24 hours
Order
routine

Why This Test Might Be Ordered

Your healthcare provider may recommend this test if you’ve had symptoms of COVID-19, recovered from it, or been exposed to someone with the virus. It can also be used to assess immunity after vaccination or to monitor long-term immune response in certain situations.

What to Expect Before the Test

No special preparation is needed. You may have a simple blood draw from a vein in your arm. The test uses a small amount of your blood to detect antibodies in your serum or plasma.

What the Test Results Mean

Positive results indicate the presence of antibodies against the virus’s nucleocapsid protein, suggesting prior infection. Negative results mean no detectable antibodies, which could mean you haven’t been infected recently or your immune response hasn’t produced these antibodies yet.

Common Reasons for Testing

This test is often used to confirm past COVID-19 infection, evaluate vaccine-induced immunity, or screen for asymptomatic carriers in certain settings.

Clinical interpretation

How abnormal results are interpreted and what conditions they suggest.

Clinical Significance: This test helps distinguish between active infection (detected by viral testing) and past infection, which is important for understanding immunity and guiding public health or vaccination strategies. It’s not a diagnostic tool for current illness but can inform long-term health monitoring.

Short name

Anti-Nucleocapsid Antibody

Frequently asked questions

Can this test detect COVID-19 if I’m currently sick?
No, this test specifically looks for antibodies produced after infection, not the virus itself. If you’re currently symptomatic, a viral test (like PCR or antigen test) would be needed to diagnose active COVID-19.
How long after infection can I expect to see positive results?
Antibody levels typically appear within 2–3 weeks after infection but may take longer in some people. Results can vary based on immune response and testing sensitivity.
Does this test replace a viral test for diagnosing COVID-19?
No, this test is not a replacement for viral tests (like PCR or rapid antigen tests) to diagnose active COVID-19. It’s used for different purposes, such as assessing immunity or past exposure.
  1. 1
  2. 2
  3. 3

Click any link to access the full source. PubMed Central (PMC) links provide free full-text access.

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Medical Disclaimer

This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.

If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.

Medically reviewed by WellAlly Editorial Team Last reviewed August 16, 2026. · Read our editorial policy